{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:51:41Z","timestamp":1791409901894,"version":"4.3.3"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100016077","name":"Dongguan Science and Technology Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016077","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020742","name":"State Key Laboratory of Anti-Infective Drug Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020742","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bioorg.2026.110285","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:36:55Z","timestamp":1785253015000},"page":"110285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design, synthesis and evaluation of benzo[4,5]thiazolo[3,2-a]pyrimidin-4-one derivatives as novel MTA cooperative PRMT5 inhibitors for the treatment of MTAP-deleted cancers"],"prefix":"10.1016","volume":"181","author":[{"given":"Bing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Jing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Guang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Shan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9446-5117","authenticated-orcid":false,"given":"Fang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.bioorg.2026.110285_bb0005","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s00018-009-0010-x","article-title":"The protein arginine methyltransferase family: an update about function, new perspectives and the physiological role in humans","volume":"66","author":"Wolf","year":"2009","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110285_bb0010","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1038\/s41467-021-21963-1","article-title":"Profiling PRMT methylome reveals roles of hnRNPA1 arginine methylation in RNA splicing and cell growth","volume":"12","author":"Li","year":"2021","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110285_bb0015","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1016\/j.celrep.2018.08.002","article-title":"PRMT5 regulates DNA repair by controlling the alternative splicing of histone-modifying enzymes","volume":"24","author":"Hamard","year":"2018","journal-title":"Cell Rep."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110285_bb0020","doi-asserted-by":"crossref","first-page":"199","DOI":"10.15698\/cst2020.08.228","article-title":"PRMT5 function and targeting in cancer","volume":"4","author":"Kim","year":"2020","journal-title":"Cell Stress"},{"issue":"9","key":"10.1016\/j.bioorg.2026.110285_bb0025","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1111\/j.1349-7006.2012.02367.x","article-title":"Protein arginine methyltransferase 5 is a potential oncoprotein that upregulatesG1 cyclins\/cyclin-dependent kinases and the phosphoinositide 3-kinase\/AKTsignaling cascade","volume":"103","author":"Wei","year":"2012","journal-title":"Cancer Sci."},{"issue":"16","key":"10.1016\/j.bioorg.2026.110285_bb0030","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1158\/0008-5472.CAN-11-0458","article-title":"Protein arginine methyltransferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor programmed cell death 4","volume":"71","author":"Powers","year":"2011","journal-title":"Cancer Res."},{"issue":"6278","key":"10.1016\/j.bioorg.2026.110285_bb0035","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1126\/science.aad5214","article-title":"MTAP deletion confers enhanced dependency on the arginine methyltransferase PRMT5 in human cancer cells","volume":"351","author":"Kryukov","year":"2016","journal-title":"Science"},{"issue":"6278","key":"10.1016\/j.bioorg.2026.110285_bb0040","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.aad5944","article-title":"Disordered methionine metabolism in MTAP\/CDKN2A-deleted cancers leads to dependence on PRMT5","volume":"351","author":"Mavrakis","year":"2016","journal-title":"Science"},{"issue":"24","key":"10.1016\/j.bioorg.2026.110285_bb0045","doi-asserted-by":"crossref","first-page":"11956","DOI":"10.3390\/ijms262411956","article-title":"MTAP deletion as a therapeutic vulnerability in cancer: from molecular mechanism to clinical targeting","volume":"26","author":"Krawczyk","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110285_bb0050","volume":"6","year":"2016","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110285_bb0055","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1158\/2159-8290.CD-24-0887","article-title":"AMG 193, a clinical stage MTA-cooperative PRMT5 inhibitor, drives antitumor activity preclinically and in patients with MTAP-deleted cancers","volume":"15","author":"Belmontes","year":"2025","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110285_bb0060","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1021\/acs.jmedchem.4c03067","article-title":"Discovery of TNG462: a highly potent and selective MTA-cooperative PRMT5 inhibitor to target cancers with MTAP deletion","volume":"68","author":"Cottrell","year":"2025","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110285_bb0065","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"issue":"20","key":"10.1016\/j.bioorg.2026.110285_bb0070","first-page":"2391","article-title":"Phase I\/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms","volume":"15","author":"Watts","year":"2024","journal-title":"Ther. Adv. Hemato."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110285_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102961","article-title":"A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations","volume":"9","author":"Rodon","year":"2024","journal-title":"ESMO Open"},{"issue":"12","key":"10.1016\/j.bioorg.2026.110285_bb0080","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.tibs.2011.09.001","article-title":"Versatility of PRMT5-induced methylation in growth control and development","volume":"36","author":"Karkhanis","year":"2011","journal-title":"Trends Biochem. Sci."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110285_bb0085","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1021\/acs.jmedchem.4c00133","article-title":"Discovery of TNG908: a selective, brain penetrant, MTA-cooperative PRMT5 inhibitor that is synthetically lethal with MTAP-deleted cancers","volume":"67","author":"Cottrell","year":"2024","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110285_bb0090","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1021\/acs.jmedchem.1c01900","article-title":"Fragment-based discovery of MRTX1719, a synthetic lethal inhibitor of the PRMT5\u2022MTA complex for the treatment of MTAP-deleted cancers","volume":"65","author":"Smith","year":"2022","journal-title":"J. Med. Chem."},{"issue":"7_Supplement","key":"10.1016\/j.bioorg.2026.110285_bb0095","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1158\/1538-7445.AM2026-4489","article-title":"Abstract 4489: CAAP1 loss uncovers vulnerability of MTAP-deficient NSCLC to PRMT5 inhibition with AZD3470","volume":"86","author":"Urosevic","year":"2026","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110285_bb0100","doi-asserted-by":"crossref","first-page":"6932","DOI":"10.1021\/acs.jmedchem.4c03121","article-title":"Discovery of AMG 193, an MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted cancers","volume":"68","author":"Pettus","year":"2025","journal-title":"J. Med. Chem."},{"issue":"8_Supplement_1","key":"10.1016\/j.bioorg.2026.110285_bb0105","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1158\/1538-7445.AM2025-4229","article-title":"Abstract 4229: GTA182: a potentially best-in-class, MTA-cooperative PRMT5 inhibitor for MTAP-deleted advanced solid tumors","volume":"85","author":"Mao","year":"2025","journal-title":"Cancer Res."},{"issue":"8_Supplement_1","key":"10.1016\/j.bioorg.2026.110285_bb0110","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1158\/1538-7445.AM2025-2996","article-title":"Abstract 2996: TNG462, an MTA-cooperative PRMT5 inhibitor, demonstrates strong efficacy in combination with clinically relevant targeted therapies in MTAP-null preclinical models","volume":"85","author":"Zhang","year":"2025","journal-title":"Cancer Res."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826008217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826008217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:12:58Z","timestamp":1791407578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826008217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":22,"alternative-id":["S0045206826008217"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110285","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and evaluation of benzo[4,5]thiazolo[3,2-a]pyrimidin-4-one derivatives as novel MTA cooperative PRMT5 inhibitors for the treatment of MTAP-deleted cancers","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110285","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110285"}}